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A B S T R A C T
Objectives: Hepatitis C virus (HCV) clearance rate (fclearance) is deﬁned as the proportion of infected persons
who will spontaneously clear their infection after acute infection. We aimed to estimate fclearance using a
novel approach that avoids limitations in existing estimates, and to clarify the link between fclearance and
HCV viremic rate—the latter being the proportion of RNA positivity among those antibody positive.
Methods: A mathematical model was developed to describe HCV transmission. fclearancewas estimated by
ﬁtting the model to probability-based and nationally representative population-based data for Egypt
(Egypt 2008 and Egypt 2015) and USA (NHANES A and NHANES B). Uncertainty and sensitivity analyses
were conducted.
Results: fclearance was estimated at 39.9% (95% uncertainty interval (UI): 34.3%–46.4%) and 33.5% (95% UI:
29.2%–38.3%) for Egypt 2008 and Egypt 2015 data, respectively; and at 29.6% (23.0%–37.1%) and 39.9%
(31.2%–51.0%) for NHANES A and NHANES B data, respectively. fclearancewas found related to HCV viremic
rate through (approximately) the formula fclearance = 1.16 (1  HCV viremic rate). HCV viremic rate was
higher with higher risk of HCV exposure. Robustness of results was demonstrated in uncertainty and
sensitivity analyses.
Conclusion: One-third of HCV-infected persons clear their infection spontaneously, higher than earlier
estimates—the immune-system capacity to clear HCV infection may have been underestimated.
© 2018 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Introduction
Hepatitis C virus (HCV), ﬁrst identiﬁed in 1989 (Choo et al.,
1989; Kuo et al., 1989), is a major cause of liver ﬁbrosis, cirrhosis,
and cancer (Hajarizadeh et al., 2013). It is estimated that 1–3% of
the population in most countries are infected with HCV (Mohd
Hanaﬁah et al., 2013; Lavanchy, 2011). A key highlight of the
natural history of HCV infection is that a proportion of infected
persons spontaneously clear the infection after enduring acute
infection (Hajarizadeh et al., 2013). Earlier studies, following the
discovery of the virus, suggested that only 10–15% of infected
persons clear their infection (Di Bisceglie, 2000). Having an
accurate and precise estimate of HCV clearance rate is important
for HCV response, and will inform HCV treatment in early infection,
planning of health services provision, and estimation and
projections of HCV chronic infections and disease burden (Micallef
et al., 2006; Grebely et al., 2014).
With the interest in clarifying HCV natural history, a number of
longitudinal cohort studies were conducted and reported their
ﬁndings in recent years (Micallef et al., 2006; Grebely et al., 2014;
Amin et al., 2007; Seeff, 2002; Soriano et al., 2008). Although
different studies have had different lengths of follow-up, making
comparability less certain, they estimated a broad range for HCV
clearance of 0%–57% within 6–48 months after infection (Micallef
et al., 2006; Grebely et al., 2014; Amin et al., 2007; Seeff, 2002;
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Soriano et al., 2008)—the best estimate was about 25% after an
acute-infection duration of 16.5 weeks (Micallef et al., 2006;
Grebely et al., 2014). These studies have also indicated that
infection clearance is predicated on a complex interplay of host
and virus factors (Hajarizadeh et al., 2013) such as female sex
(Micallef et al., 2006; Grebely et al., 2014; Page et al., 2009), IL28B
CC genotype (Grebely et al., 2014), and HCV genotype 1 (Grebely
et al., 2014), among others (Ray et al., 1999; Li and Lemon, 2013;
Lemon, 2010; Takaki et al., 2000).
While cohort studies provide a direct approach to estimating
HCV clearance rate, this approach suffers from methodological
limitations and potential biases (Micallef et al., 2006; Amin et al.,
2007). The heterogeneity across studies in design, study popula-
tion, sample size, inclusion criteria, length of follow-up duration,
and analysis method contributed to a broad range of estimates and
added complexity to the estimates’ interpretation and compara-
bility (Amin et al., 2007; Micallef et al., 2007). Reported clearance
rates were often based on small samples of less than 50
participants and follow-up durations of less than 12 months,
though evidence suggests that undetectable RNA levels could be
reached over longer time intervals of up to 48 months (Amin et al.,
2007; Micallef et al., 2007). Several studies opted for retrospective
testing of stored HCV RNA samples for the assessment of clearance,
but there are known limitations for samples stored under
suboptimal conditions (Amin et al., 2007; Micallef et al., 2007).
The recruitment of participants may have been a key limitation
in these studies and poses a question about their representative-
ness and generalizability. Studies tended to recruit individuals who
were symptomatic and viremic at baseline (Micallef et al., 2006;
Amin et al., 2007), but HCV infection is mostly asymptomatic
(Hajarizadeh et al., 2013)—only few studies assessed clearance rate
among sero-incident cases (Micallef et al., 2006; Page et al., 2009).
Most studies recruited opportunistically from populations such as
people who inject drugs (PWID), or post-transfusion HCV patients.
The risk of reinfection in these populations is often high, and this
could have inﬂuenced the identiﬁcation of a unique acute infection
(Micallef et al., 2006). PWID, a marginalized population by
deﬁnition, may not have been also representative of the socio-
demographic characteristics, prevailing HCV genotypes, or mode of
acquisition and associated inoculum effect, of incident infections
in the population at large (Hajarizadeh et al., 2013; Grebely et al.,
2014; Pawlotsky et al., 1995; Messina et al., 2015). For example,
females have a higher clearance rate than males (Grebely et al.,
2014), but are often under-represented in the predominantly male
PWID populations (Mumtaz et al., 2014). The difﬁculty in detecting
asymptomatic acute infections, and the lack of a reliable diagnostic
test to differentiate between acute and chronic infection stages
may have as well affected the validity of clearance rate estimates,
and their representativeness of clearance in the population at large
(Amin et al., 2007).
Another critical limitation in existing studies relates to the
heterogeneity in clearance deﬁnition in terms of using a single HCV
Ribonucleic Acid (RNA) negative test, as opposed to two negative
tests within a period of one to six months (Micallef et al., 2006;
Grebely et al., 2014; Amin et al., 2007). It has been further shown
that even slight variations in case deﬁnition and analysis method
can underestimate clearance rate (Micallef et al., 2006), and
generate estimates ranging from 14% to 68%, on the same primary
data (Amin et al., 2007).
In light of these largely unavoidable limitations in cohort
studies, there is a need to provide an estimate of clearance rate
using a methodology that is independent of these limitations. We
present here a novel approach to estimate HCV clearance rate
(fclearance)—deﬁned as the proportion of HCV infected persons who
spontaneously clear their infection after the acute stage of
infection. This approach also clariﬁes the subtle link between
fclearance and HCV viremic rate, with the latter being deﬁned as the
proportion of individuals who are HCV antibody (Ab) positive and
HCV RNA positive, out of all who are HCV Ab positive regardless of
RNA status, as measured in a given cross-sectional survey. Of note
is that fclearance and HCV viremic rate are technically not rates, but
are strictly proportions with no time unit, and therefore should not
in principle be labelled as rates. However, to avoid confusion with
prevailing convention, we labeled them accordingly for consisten-
cy with existing literature, where these two measures have been
labelled as “rates”.
The fundamental concept of the present approach is that HCV
natural history effects at the individual level manifest themselves
at the population level. Starting from probability-based and
nationally representative population-level data, we used mathe-
matical modeling and simulations of the infection process to
estimate the average HCV clearance rate in the population.
Though this approach relies on an indirect method, the strength
of this analysis lies in its independence from most of the biases and
limitations affecting current empirical measures. The approach
also capitalizes on the availability of quality population-based
data, and provides an estimate that is representative of the socio-
demographic and mode of acquisition diversity in the population
at large. In a sense, this approach is effectively equivalent to
conducting a cohort study for the entire population of a country,
but in silico.
Materials and methods
Conceptual framework and key deﬁnitions
We used a conceptual framework for HCV natural history based
on current knowledge of HCV biology (Figure 1) (Hajarizadeh et al.,
2013). Infected persons are assumed to develop primary acute
infection. A fraction (fclearance) of these individuals clear their
infection spontaneously after the acute stage of infection, while the
rest (1  fclearance) become chronically infected and positive for both
HCV Ab and HCV RNA. For those who clear their infection, they can
be re-infected, and thus go through a secondary acute infection
stage. A proportion of the latter individuals will clear the infection
while the rest become chronically infected.
To avoid confusion of subtle and closely related measures,
Figure 1 includes also the exact deﬁnitions used in the present
study for HCV clearance rate and HCV viremic rate.
Figure 1. Conceptual framework and key deﬁnitions for hepatitis C virus (HCV)
natural history.
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Model description
A deterministic compartmental model was developed to
describe HCV transmission in the population at large (Figure S1
in Supplementary material (SM)). The model is an extension of
previous models (Vickerman et al., 2007; Vickerman et al., 2012;
Deufﬁc-Burban and Yazdanpanah, 2013; Ayoub and Abu-Raddad,
2017; Ayoub et al., 2018), and consists of a system of coupled
nonlinear differential equations that stratify the population
according to HCV status and stage of infection, and level of risk
of exposure (SM). To account for heterogeneity in risk of exposure
in the population, the model incorporates 15 risk groups covering a
spectrum of HCV exposure risk, from low (say blood donors or
pregnant women) to high risk, with the three highest risk groups in
the model representing PWID.
Informed by earlier work (Ayoub and Abu-Raddad, 2017; Ayoub
et al., 2018; Handcock and Jones, 2004; Hamilton et al., 2008;
Cuadros et al., 2011; Omori et al., 2015), we assumed that the
distribution of the population across risk groups follows a gamma
distribution (SM). Individuals who leave their risk group are
distributed proportionally across all risk groups. The mixing
between individuals in the different risk groups is determined by a
mixing matrix (SM) that allows a range of mixing behaviors
varying from fully assortative (mixing only with individuals in the
same risk group) to fully proportionate (mixing with individuals
with no preferential bias for any speciﬁc risk group) (Garnett and
Anderson, 1993; Awad and Abu-Raddad, 2014).
Risk of infection was captured by the force of infection that
factors in the effective number of contacts conducive for HCV
transmission, HCV transmission probability, and mixing among
risk groups (SM). We assumed that the distribution of risk of
exposure across the different risk groups follows a power law
function (SM), as suggested by earlier modeling analyses (Ayoub
and Abu-Raddad, 2017; Ayoub et al., 2018; Awad and Abu-Raddad,
2014; Barendregt et al., 2003; Barrat et al., 2004). Further details on
the model structure can be found in SM.
Model parameterization
We parameterized our model using current HCV natural
history and transmission data (Table S1 in SM). The model was
applied to two countries—Egypt and the United States of America
(USA)—where HCV biomarker data for the population at large has
been collected through rigorous probability-based and nationally
representative surveys. The Egypt data were derived from the
2008 and 2015 Egypt Demographic and Health Surveys (EDHS)
(El-Zanaty and Way, 2009; Ministry of Health and Population
[Egypt] et al., 2015). HCV Ab prevalence was estimated at 14.7%
(95% conﬁdence interval (CI): 14.0–15.4%) in 2008 and at 10.0%
(95% CI: 9.3–10.7%) in 2015. HCV viremic rate was assessed at
67.1% (95% CI: 64.5–69.6%) in 2008 and at 70.2% (95% CI: 67.2–
73.1%) in 2015. For ease of reference, these two data sources have
been labeled thereafter as Egypt 2008 and Egypt 2015,
respectively.
The USA data were derived from the continuous series of the
National Health and Nutrition Examination Surveys (NHANES)
(NHANES, 1999–2012NHANES, 1999NHANES, 1999–2012). HCV Ab
prevalence and HCV viremic rate were estimated for each NHANES
round between 1999 and 2012 (before the recent scale up in
treatment), and then pooled using DerSimonian-Laird random-
effects meta-analyses (DerSimonian and Laird, 1986). Pooled HCV
Ab prevalence was estimated at 1.4% (95% CI: 1.3–1.6%), and pooled
HCV viremic rate was estimated at 74.0% (95% CI: 57.9–79.6%). This
data source has been labeled thereafter as NHANES A.
Since NHANES laboratory procedures entail the additional
testing of individuals with undetermined HCV Ab results for HCV
RNA positivity, we also derived a second pooled estimate for the
NHANES viremic rate including as denominator both individuals
conﬁrmed as HCV Ab positive and those with an undetermined
HCV Ab status. This yielded a viremic rate of 64.6% (95% CI: 56.2–
72.6%). This data source has been labeled thereafter as NHANES B.
The model was additionally applied to six countries where HCV
biomarker data were available through population-based surveys,
but without sufﬁcient description of the methodology to assess
whether the data where collected using strictly probability-based
and nationally representative sampling of standardized and
comparable methodology to that of the EDHS and NHANES
surveys. These included surveys from Brazil (Pereira et al., 2013),
India (Lee et al., 2014), Ireland (Thornton et al., 2012), Latvia
(Tolmane et al., 2011), Netherlands (Vriend et al., 2012), and
Vietnam (Do et al., 2014).
Data on the population proportion of PWID, a key determinant
of HCV epidemiology across countries, were retrieved from global
and regional reviews (Mumtaz et al., 2014; Aceijas et al., 2004;
Lansky et al., 2014).
Model ﬁtting
We estimated the population fclearance by ﬁtting model output to
HCV Ab prevalence, HCV viremic rate, and the population
proportion of PWID for each country, assuming endemic equilib-
rium. Model ﬁts were implemented in MATLAB1 (MATLAB1, 2013)
using a nonlinear least-square ﬁtting method based on the Nelder-
Mead simplex algorithm, described in Lagarias et al. (Lagarias et al.,
1998).
Uncertainty analysis
We conducted multivariable uncertainty analyses to determine
the range of uncertainty around our estimates for fclearance by
varying the model parameters. We speciﬁcally implemented 500
runs of the model applying at each run Monte Carlo sampling from
uniform probability distributions that were generated from either
the CI, or assuming (if uncertainty is not captured by CI) 25%
uncertainty around the point estimates of these parameters. In
each run, the parameters’ values were randomly selected from
their speciﬁed ranges, and the model was reﬁtted to data.
The parameters included in the uncertainty analyses are HCV
transmission probability for the different stages of infection,
duration of each infection stage, proportion of individuals in
secondary acute infection who clear their infection spontaneously,
HCV viremic rate in each setting, duration that an individual
spends in a speciﬁc risk group, the degree of assortativeness in the
mixing, the scale parameter in the gamma distribution of the
population across risk groups, and the exponent parameter in the
power law function of the distribution of risk of exposure. The
mean of the resulting distribution for fclearance and its associated
95% uncertainty interval (UI) were derived.
Sensitivity analyses
Several sensitivity analyses were conducted using the Egypt
2008 model as an illustrative example. These analyses assessed the
robustness of our predictions for fclearance to variations in key
measures or parameters that may not be known with sufﬁcient
precision, or suspected to potentially inﬂuence our predictions.
These measures or parameters included HCV Ab prevalence in the
population, statistical distribution of the duration of primary acute
infection, statistical distribution of the population across the 15
risk groups, risk of exposure variation among the 15 risk groups in
the model, and fraction of individuals in secondary acute infection
who clear their infection spontaneously.
62 H.H. Ayoub et al. / International Journal of Infectious Diseases 75 (2018) 60–66
We further conducted two additional sensitivity analyses. In the
ﬁrst analysis, we estimated fclearance in Egypt by ﬁtting the model
output to the actual temporal variation in HCV Ab prevalence, that
is by relaxing the assumption of endemic equilibrium. In the
second sensitivity analysis, using the Egypt 2008 model as an
illustrative example, we assessed the robustness of our estimate
for fclearance to large variations in the uncertainty of the input
parameters by allowing 50% uncertainty around the point
estimates, instead of only 25%.
Results
Robust model ﬁts were obtained for the ﬁtted epidemiological
measures in all country-speciﬁc estimations (Table S2 in SM). In
Egypt, fclearance was estimated at 39.9% (95% UI: 34.3%–46.4%) for
Egypt 2008, and at 33.5% (95% UI: 29.2%–38.3%) for Egypt 2015 data
(Figure 2). In the USA, fclearance was estimated at 29.6% (23.0%–
37.1%) for NHANES A, and at 39.9% (31.2%–51.0%) for NHANES B
data (Figure 2).
Figure 3 shows the estimated fclearance versus HCV viremic rate
in the population using (in addition) the survey data from Brazil
(Pereira et al., 2013), India (Lee et al., 2014), Ireland (Thornton et al.,
2012), Latvia (Tolmane et al., 2011), Netherlands (Vriend et al.,
2012), and Vietnam (Do et al., 2014). Figure 3 also shows the
functional relationship between the estimated fclearance and HCV
viremic rate, as generated using the Egypt 2008 model as an
illustrative example. fclearance was found to linearly depend on HCV
viremic rate. The best ﬁt line to the model predictions yielded the
following linear relationship:
f clearance ¼ 1:16 1  HCV viremic rate from populationð
based surveyÞ ð1Þ
All country-speciﬁc estimates for fclearance, from each individual
country-speciﬁc model, were found to lie very close to the curve
generated using the Egypt 2008 model (by changing the
background population antibody prevalence).
The above result establishes the functional relationship
between fclearance and HCV viremic rate in the whole population,
but HCV viremic rate is most often measured for speciﬁc risk
populations, such as PWID, rather than for the whole population
using probability-based and nationally representative surveys.
Figure 4 shows the estimated HCV viremic rate for each risk group
of the modeled 15 risk groups in the population, using the Egypt
2008 and NAHNES A models as illustrative examples. The ﬁgure
further displays HCV viremic rate for the whole population and
indicates fclearance as estimated above for each of Egypt 2008 and
NHANES A.
HCV viremic rate was found to increase with the level of risk of
exposure to HCV infection, and was highest among groups at
highest risk, particularly PWID (Figure 4). In the higher risk groups,
HCV viremic rate can be substantially higher than the HCV viremic
rate in the whole population—it could not be used to estimate
fclearance using Eq. (1). Meanwhile, HCV viremic rate in the lower
risk populations (say blood donors or pregnant women) was found
to be closer to HCV viremic rate in the whole population (with
slight underestimation)—it could be used to estimate approxi-
mately fclearance using Eq. (1).
The ﬁve conducted sensitivity analyses assessing the robustness
of our predictions to variations in the key measures or parameters
afﬁrmed the robustness of the estimates for fclearance (Figure S2). They
also demonstrated the impact of variations in the different input
parameters on the estimated fclearance. Only small variations were
observed in the estimated fclearancedespite extreme variations in the
measures and parameters that may not be known with sufﬁcient
precision, or suspected to potentially inﬂuence our predictions.
In the additional sensitivity analysis assessing the impact of
relaxing the assumption of endemic equilibrium, the estimated
Figure 2. Estimated mean and 95% uncertainty interval (UI) for hepatitis C virus
(HCV) clearance rate (fclearance). The estimates were conducted based on data from
the 2008 and 2015 Egypt Demographic and Health Surveys (EDHS) and the
continuous series of the National Health and Nutrition Examination Surveys
(NHANES).
Figure 3. Relationship between hepatitis C virus (HCV) clearance rate (fclearance) and HCV viremic rate in the whole population. The ﬁgure shows (solid line) the functional
relationship between the estimated fclearance and HCV viremic rate in the whole population, as generated using the Egypt 2008 model (by varying background antibody
prevalence in the population), as an illustrative example. The ﬁgure shows also fclearance versus HCV viremic rate in the whole population as estimated using 10 different
population-based survey data.
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fclearance for Egypt was 37.5%, within the range of the estimates
assuming endemic equilibrium, thereby afﬁrming our conclusions.
In the sensitivity analysis assessing the impact of large uncertainty
in the input parameters, fclearance for Egypt 2008 was estimated at
39.3% (95% UI: 33.4%–46.1%)—afﬁrming also our conclusions
despite the larger uncertainty interval.
Discussion
We estimated HCV clearance rate (fclearance) using a novel
analytical approach that avoids most limitations of the estimates of
longitudinal cohort studies. We found that fclearance is in the range
of 30–40%—substantially higher than the best estimates of cohort
studies of about 25% (Micallef et al., 2006; Grebely et al., 2014). We
also derived a simple relationship that can predict fclearance in the
whole population from a measure of HCV viremic rate in this
population (Eq. (1)). While quality probability-based and nation-
ally representative measures of HCV viremic rate may not be
available for most countries, we found that HCV viremic rate in low
risk populations, such as blood donors or pregnant women, can
approximately represent HCV viremic rate in the whole popula-
tion, and could be used to estimate fclearance for this population.
Meanwhile, we found that HCV viremic rate in high risk
populations, such as PWID, may not be representative of that in
the whole population and should not be used to infer fclearance in the
population.
Our ﬁnding that existing empirical measures from longitudinal
cohort studies are likely to have underestimated HCV spontaneous
clearance should not be surprising. Cohort studies reported
inconsistent estimates that ranged between 0%–57% (Micallef
et al., 2006; Grebely et al., 2014; Amin et al., 2007; Seeff, 2002). A
broad range of limitations have also been identiﬁed in these
studies, as reviewed in the introduction section above, and these
limitations could have affected these studies, as well as their
generalizability and representativeness.
While we introduced a method for estimating fclearance from HCV
viremic rate, existing literature suggests large variations in
measured HCV viremic rate (Harfouche et al., 2017). Figure 3
demonstrates this variability for the 10 population-based meas-
ures of HCV viremic rate from different countries. While it is
conceivable that there could be true variations in HCV viremic rate
reﬂecting underlying heterogeneity in the factors that affect
spontaneous clearance such as the population proportion of PWID,
type of population affected by HCV infection, gender, circulating
genotype, and level of HIV coinfection, we are more inclined to
believe that this variability arises mainly from differences in the
complex laboratory methods used to assess HCV viremic rate.
Assessment of HCV viremic rate requires a two-test algorithm,
for HCV Ab and HCV RNA, and the diagnostic assays and protocols
can vary from one study to another. Even small variation in analysis
methods, such as deﬁnition of the denominator in HCV viremic
rate, can lead to large variations in the estimated rate. An example
to this end can be seen in the difference between the two estimates
of NHANES A and NHANES B, where the difference relates solely to
how the denominator was deﬁned. Another example is the
variation in the viremic rate in NHANES in recent rounds versus
earlier rounds, which in part may be due to a minor change in the
testing protocol starting from 2013 (Centers for Disease Control
and Prevention, 2016, 2018a, 2018b).
A recent comprehensive systematic meta-analysis of HCV
viremic rate measures in diverse populations in the Middle East
and North Africa supports this conjecture (Harfouche et al., 2017).
Though HCV viremic rate was found to vary extensively across
studies, the pooled means were similar irrespective of country or
subregion, population HCV Ab prevalence, or study sampling
method, among other factors. The overall pooled mean of all 178
measures was estimated at 67.6% (95% CI: 64.9–70.3%), closely
similar to the probability-based and nationally representative
estimates of the EDHS and NHANES (El-Zanaty and Way, 2009;
Ministry of Health and Population [Egypt] et al., 2015; NHANES,
1999–2012NHANES, 1999NHANES, 1999–2012). These consider-
ations advocate for use of one standardized methodology for the
deﬁnition and measurement of HCV viremic rate in the literature.
This will not only facilitate estimation of fclearance in a given
population, but (importantly) it will facilitate the use of the
viremic rate for assessing and monitoring the scale up and
coverage of HCV treatment programs, as we progress towards the
target of HCV elimination by 2030 (World Health Organization,
2016).
Our study has limitations. The introduced approach for
estimating fclearance is best implemented on probability-based
and nationally representative data, but such data are not yet
Figure 4. Hepatitis C virus (HCV) viremic rate for each HCV risk group of the modeled 15 risk groups in the population, using the Egypt 2008 and NAHNES A models as
illustrative examples. The ﬁgure also shows HCV viremic rate for the whole population.
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available in most countries. In absence of a standardized
methodology for estimating HCV viremic rate, measures will tend
to vary widely curtailing the utility of the introduced method to
estimate fclearance. A pooled measure (over many studies) for the
viremic rate, instead of a study-speciﬁc measure, may alleviate this
challenge as has been shown recently in the systematic meta-
analysis of HCV viremic rate data (Harfouche et al., 2017). We used
an elaborate mathematical model to capture the complexity of
HCV dynamics, but some of our model assumptions may not hold
and this could have affected our predictions. However, our model
yielded robust ﬁts to the epidemiological measures (Table S2 in
SM), and we performed multiple sensitivity analyses on the model
output to assess the robustness of our estimates—these analyses
afﬁrmed our ﬁndings (Figure S2).
We did not incorporate treatment coverage for HCV chronically
infected individuals, but treatment coverage has been very low up
to the recent scale up of direct-acting antivirals (DAAs) programs
(Ayoub and Abu-Raddad, 2017; World Health Organization, 2016;
Polaris Observatory, 2018; Egypt Ministry of Health and Popula-
tion, 2014), and therefore could not have affected the model input
data, such as those of EDHS and NHANES, or the model output. We
assumed that those exposed to HCV infection will be HCV Ab
positive for life, which may have underestimated the clearance rate
if considerable fraction of individuals lose their antibodies over
time. We assessed the clearance rate in Egypt and USA where the
dominant genotypes are 4 (Mahmud et al., 2018) and 1 (Klevens
et al., 2012), respectively, but these results may not be generaliz-
able to other settings where other genotypes, such as genotype 3
(Messina et al., 2015), are dominant. For simplicity, we did not
explicitly incorporate gender or full dynamics details of injecting
drug use in the model.
Our study has key strengths. We used a novel approach to
estimate fclearance that builds on the success of related approaches
applied for HIV infection (Bellan et al., 2015; Chemaitelly et al.,
2014) among other infections (Omori et al., 2018). Our approach
provided an independent estimate for fclearance that avoids most
limitations of empirical measures. fclearance estimation was based
on state of the art population-based input data generated through
rigorous probability-based and nationally representative sam-
pling. The fclearance estimates were also generated as averages for
the whole population, and therefore are representative of the
diversity of factors that exists in the whole population (and may
affect clearance) such as socio-demography, mode of acquisition
and associated inoculum effect, heterogeneity in risk of exposure,
interplay of host and virus factors, infection symptoms, and risk of
reinfection. This is to be contrasted with cohort studies that recruit
from speciﬁc settings and populations, such as PWID, who may not
be representative of the wider population exposed to HCV
infection.
Moreover, existing literature (Micallef et al., 2006; Grebely
et al., 2014; Amin et al., 2007; Harfouche et al., 2017) supports our
modeling results that the viremic rate is higher among PWID than
among the wider population. For example, the viremic rate in the
NHANES A analysis was 74.9% (67.3–81.9%) among PWID versus
69.9% (59.2–79.7%) in the wider population—while the difference
is not statistically signiﬁcant, it is suggestive of higher viremic rate
among PWID.
Importantly, we introduced a simple equation for deriving
fclearance from HCV viremic rate, and this equation clariﬁes the
subtle link between fclearance and HCV viremic rate, two distinct
measures that seem often to be confused as one measure. The
fclearance estimate was found higher than estimated using the
simplistic formula f clearance ¼ 1  HCV viremic rateð Þ. The differ-
ence is due to reinfection, as people who clear their infection can
be re-exposed leading to chronic infection despite earlier
clearance, as well as to the ﬁnite and not too small months-long
duration of primary acute infection.
Lastly, we conducted an extensive uncertainty analysis around
the estimated clearance rates. This analysis captured more sources
of uncertainty than possible through conventional maximum
likelihood parameter-estimation methods. For example, the
estimated clearance rates for Egypt 2008 and NHANES A using a
maximum likelihood approach are 39.9% (95% CI: 39.8–40.3%) and
29.6% (95% CI: 29.3–29.8%), respectively—the narrow conﬁdence
intervals being a consequence of the very large sample sizes of
these national surveys.
In conclusion, about one-third of HCV infected persons clear
their infection spontaneously, indicating that empirical measures
from longitudinal cohort studies may have underestimated the
capacity of the host immune system to clear HCV infection. This
ﬁnding has implications for the ongoing efforts to estimate HCV
infection burden, and to plan for health services provision. This
ﬁnding also may have implications for our understanding of the
biological determinants of HCV spontaneous clearance. It may
hint that a strategy for HCV vaccine development could be a
vaccine that does not necessarily prevent infection, but modu-
lates immune response towards conditions that increase the
capacity of the host immune system to clear HCV infection
spontaneously.
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